Gavreto (pralsetinib)

News alerts, weekly reports and conference planners

Company:

Allist, Blueprint Medicines, CStone Pharma, Rigel

Drug class:

RET inhibitor

Related drugs:

RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Hurthle Cell Carcinoma	RET fusion	Thyroid Gland Hurthle Cell Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Follicular Carcinoma	RET fusion	Thyroid Gland Follicular Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Anaplastic Carcinoma	RET fusion	Thyroid Gland Anaplastic Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Biliary Tract Cancer	RET fusion	Biliary Tract Cancer	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Pancreatic Cancer	RET fusion	Pancreatic Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Cholangiocarcinoma	RET fusion	Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Pancreatic Adenocarcinoma	RET fusion	Pancreatic Adenocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Colon Cancer	RET fusion	Colon Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Salivary Gland Cancer	RET fusion	Salivary Gland Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Lung Adenocarcinoma	RET fusion	Lung Adenocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Neuroendocrine Tumor	RET fusion	Neuroendocrine Tumor	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Sarcoma	RET fusion	Sarcoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Head and Neck Cancer	RET fusion	Head and Neck Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET fusion	Solid Tumor	RET fusion	Solid Tumor	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
RET V804*	Thyroid Gland Medullary Carcinoma	RET V804*	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
RET C634*	Thyroid Gland Medullary Carcinoma	RET C634*	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	selpercatinib + pralsetinib Sensitive: C3 – Early Trials selpercatinib + pralsetinib Sensitive : C3	selpercatinib + pralsetinib Sensitive: C3 – Early Trials selpercatinib + pralsetinib Sensitive : C3
EGFR mutation + RET fusion	Non Small Cell Lung Cancer	EGFR mutation + RET fusion	Non Small Cell Lung Cancer	osimertinib + pralsetinib Sensitive: C3 – Early Trials osimertinib + pralsetinib Sensitive : C3	osimertinib + pralsetinib Sensitive: C3 – Early Trials osimertinib + pralsetinib Sensitive : C3
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3	pralsetinib Sensitive: C3 – Early Trials pralsetinib Sensitive : C3
KIF5B-RET fusion + RET E732K	Non Small Cell Lung Cancer	KIF5B-RET fusion + RET E732K	Non Small Cell Lung Cancer	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3
KIF5B-RET fusion + RET L730V	Non Small Cell Lung Cancer	KIF5B-RET fusion + RET L730V	Non Small Cell Lung Cancer	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3
KIF5B-RET fusion + RET L730I	Non Small Cell Lung Cancer	KIF5B-RET fusion + RET L730I	Non Small Cell Lung Cancer	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3
KIF5B-RET fusion + RET G810S	Non Small Cell Lung Cancer	KIF5B-RET fusion + RET G810S	Non Small Cell Lung Cancer	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3	pralsetinib Resistant: C3 – Early Trials pralsetinib Resistant : C3
RET L629P	Thyroid Gland Medullary Carcinoma	RET L629P	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4
RET D631_R635delinsG	Thyroid Gland Medullary Carcinoma	RET D631_R635delinsG	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4	pralsetinib Sensitive: C4 – Case Studies pralsetinib Sensitive : C4

Gavreto (pralsetinib)

Associations
(49)

Associations
(49)

Gavreto (pralsetinib)

Associations(49)

Associations(49)

Associations
(49)

Associations
(49)